| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/25/2012 | EP2409969A1 Pyrimidine urea derivatives as kinase inhibitors |
| 01/25/2012 | EP2409967A1 Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
| 01/25/2012 | EP2409966A1 Aminocyclitol compounds, procedure for the obtainment and uses |
| 01/25/2012 | EP2409963A1 Use of derivatives of polyunsaturated fatty acids as medicaments |
| 01/25/2012 | EP2409732A1 Compositions and methods for bone formation and remodeling |
| 01/25/2012 | EP2409711A1 Enzyme treatment of foodstuffs for celiac sprue |
| 01/25/2012 | EP2409708A1 Compounds and methods for selectively targeting tumor-associated mucins |
| 01/25/2012 | EP2409707A1 Polymer-based sustained release device |
| 01/25/2012 | EP2409706A1 Dihydropteridinones for the treatment of cancer diseases |
| 01/25/2012 | EP2409705A1 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| 01/25/2012 | EP2409704A2 c-Met modulators and methods of use |
| 01/25/2012 | EP2409703A1 Treatment with alpha7-selective ligands |
| 01/25/2012 | EP2409702A1 Combination of siloxane and active ingredient for treating dental disorder of hard tissues |
| 01/25/2012 | EP2409701A1 Prasugrel granules with improved stability |
| 01/25/2012 | EP2409700A1 Methods of treatment using intravenous formulations comprising temozolomide |
| 01/25/2012 | EP2409699A1 Stable compositions of voriconazole |
| 01/25/2012 | EP2409698A1 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition |
| 01/25/2012 | EP2409697A1 Medicaments Based on Dinuclear Ruthenium, Osmium and Iron Complexes Comprising Triply Bridging Thiolato, Selenolato, Alkoxo and/or Amido Ligands |
| 01/25/2012 | EP2409696A1 Agent for promoting energy consumption |
| 01/25/2012 | EP2409695A1 Sn-2-Monoacylglycerols and lipid malabsorption |
| 01/25/2012 | EP2409694A1 Association of a sinus current inhibitor if and a beta blocker |
| 01/25/2012 | EP2409693A2 Isothiocyanates and derivatives for use in the treatment and / or prevention of polymorphous light eruptions |
| 01/25/2012 | EP2409692A1 Fluid application device and method |
| 01/25/2012 | EP2409691A1 Pharmaceutical cyclosporin compositions |
| 01/25/2012 | EP2409690A2 Improved stability of progestogen formulations |
| 01/25/2012 | EP2409689A1 Prasugrel tablet formulations |
| 01/25/2012 | EP2409685A2 Orally-disintegrating formulations of prasugrel |
| 01/25/2012 | EP2409681A1 Method for improving the aesthetic appearance of skin by enhancing the skin thickness |
| 01/25/2012 | EP2409156A2 Akt tyrosine 176 phosphorylation cancer biomarker |
| 01/25/2012 | EP2409152A1 Methods for modulating circadian rythms |
| 01/25/2012 | EP2408934A1 Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t (treg) cells and uses thereof |
| 01/25/2012 | EP2408916A2 RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/25/2012 | EP2408915A2 RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/25/2012 | EP2408912A1 Foxm1 peptides and vaccines containing the same |
| 01/25/2012 | EP2408906A1 Methods for modulating metabolic and circadian rhythms |
| 01/25/2012 | EP2408799A1 Novel crystalline form of antiprogestin cdb-4124 |
| 01/25/2012 | EP2408798A1 Polymorphs of fluticasone furoate and processes for preparation thereof |
| 01/25/2012 | EP2408796A1 Targeting apolipoprotein b for the reduction of apolipoprotein c-iii |
| 01/25/2012 | EP2408791A1 Fosfluconazole derivatives, synthesis, and use in long acting formulations |
| 01/25/2012 | EP2408780A2 3-oxa-7-azabicycloý3.3.1¨nonanes |
| 01/25/2012 | EP2408779A1 Compounds and biological materials and uses thereof |
| 01/25/2012 | EP2408778A1 N-[(6-aza-bicyclo[3.2.1]oct-5-yl)-aryl-methyl]-heterobenzamide derivatives, preparation thereof, and therapeutic use of same |
| 01/25/2012 | EP2408777A1 Improved chemical synthesis of diazaindoles by chichibabin cyclization |
| 01/25/2012 | EP2408776A1 Use of a kinase inhibitor for the treatment of thymoma |
| 01/25/2012 | EP2408775A1 Oxidated derivatives of triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments |
| 01/25/2012 | EP2408774A2 Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof |
| 01/25/2012 | EP2408772A1 Compounds |
| 01/25/2012 | EP2408771A2 Pyrazinoisoquinoline compounds |
| 01/25/2012 | EP2408770A2 Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials |
| 01/25/2012 | EP2408769A1 Pyrimidine derivatives used as itk inhibitors |
| 01/25/2012 | EP2408767A2 Amide derivatives as neuropeptide y5 receptor ligands |
| 01/25/2012 | EP2408766A1 Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| 01/25/2012 | EP2408763A2 Derivatives of n-ý(2-aza-bicycloý2.1.1¨hex-1-yl)-aryl-methyl¨-heterobenzamide, preparation thereof and application of same in therapeutics |
| 01/25/2012 | EP2408762A1 Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof |
| 01/25/2012 | EP2408761A1 Substituted indole derivatives and methods of use thereof |
| 01/25/2012 | EP2408760A1 Thiophenyl sulfonamides for the treatment of alzheimer's disease |
| 01/25/2012 | EP2408757A1 Novel alpha-(n-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production a novel alpha-(n-sulfonamido) acetamide compound incorporating deuterium as inhibitor of beta amyloid peptide production |
| 01/25/2012 | EP2408756A1 Alpha-(n-benzenesulfonamido)cycloalkyl derivatives |
| 01/25/2012 | EP2408755A2 Psma-targeting compounds and uses thereof |
| 01/25/2012 | EP2408754A1 Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency |
| 01/25/2012 | EP2408753A2 Compounds and methods for treating mammalian gastrointestinal microbial infections |
| 01/25/2012 | EP2408752A1 Substituted pyrimidines for the treatment of cancer |
| 01/25/2012 | EP2408751A1 Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof |
| 01/25/2012 | EP2408749A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/25/2012 | EP2408747A1 Substituted pyridine derivatives and their medical use |
| 01/25/2012 | EP2408745A1 Piperidine derivatives as nk3 receptor antagonists |
| 01/25/2012 | EP2408744A1 Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| 01/25/2012 | EP2408743A1 Carbamate derivatives in particular for the treatment of neurological disorders |
| 01/25/2012 | EP2408742A1 Anthelmintic agents and their use |
| 01/25/2012 | EP2408740A2 Compounds for treating inflammation and pain |
| 01/25/2012 | EP2408479A1 Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
| 01/25/2012 | EP2408465A2 Methods and compositions for the detection of cancer |
| 01/25/2012 | EP2408459A1 A dose of ave5026 for the treatment of venous thromboembolism in patients with severe renal impairment |
| 01/25/2012 | EP2408458A1 RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/25/2012 | EP2408457A1 Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid |
| 01/25/2012 | EP2408456A1 A dermaceutical cream made using sodium fusidate and betamethasone valerate |
| 01/25/2012 | EP2408455A2 Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders |
| 01/25/2012 | EP2408454A2 Novel anti-inflammatory agents |
| 01/25/2012 | EP2408453A1 Ophthalmic formulations of cetirizine and methods of use |
| 01/25/2012 | EP2408452A1 Compound for the treatment of tuberculosis |
| 01/25/2012 | EP2408451A2 Radiolabelled pyridinyl derivatives for in-vivo imaging |
| 01/25/2012 | EP2408450A1 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| 01/25/2012 | EP2408449A2 Methods and compositions of treating a flaviviridae family viral infection |
| 01/25/2012 | EP2408448A2 Methods and compositions of treating a flaviviridae family viral infection |
| 01/25/2012 | EP2408447A1 Prenylated bisphosphonates as anti-tuberculosis agents |
| 01/25/2012 | EP2408446A1 Use of pharmaceutical compositions containing mesembrenone |
| 01/25/2012 | EP2408445A1 Gold (iii) complexes with oligopeptides functionalized with sulfur donors and use thereof as antitumor agents |
| 01/25/2012 | EP2408444A2 Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| 01/25/2012 | EP2408443A1 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| 01/25/2012 | EP2408442A1 Pharmaceutical composition presenting anti-inflammatory properties |
| 01/25/2012 | EP2408441A1 Combination therapies for treating metabolic disorders |
| 01/25/2012 | EP2408440A1 Transdermal pharmaceutical preparation and administration of tirofiban |
| 01/25/2012 | EP2408439A1 Bioadhesive patch |
| 01/25/2012 | EP2408437A1 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients |
| 01/25/2012 | EP2408436A1 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients |
| 01/25/2012 | EP2408435A2 Compositions and methods for delivering an agent to a wound |
| 01/25/2012 | EP2408434A1 Treating alzheimer's disease and osteoporosis and reducing aging |
| 01/25/2012 | EP2408433A1 Pharmaceutical composition comprising aliskiren |
| 01/25/2012 | EP2408432A1 Macrocyclic lactone drug delivery system |
| 01/25/2012 | EP2408431A1 Solid retigabine in non-crystalline form |